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Introduction
The differentiation between atypical ductal hyperplasia 
(ADH) and in situ ductal carcinoma (DCIS) of the 
breast is very difficult and may depend on the subjective 
judgment and experience of the pathologist. Several 
studies have demonstrated that diagnosis of atypical 
ductal hyperplasia of the mammary gland is associated 
with a relatively high risk of breast cancer [1]. The 
pathogenesis of breast cancer may be heterogenous. Not 
every case of atypical hyperplasia progresses into invasive 
cancer [2, 3]. According to one model of breast tumor 
genesis, atypical hyperplasia develops from normal ductal 
cells. Further accumulation of genetic abnormalities 
leads to the development of carcinoma.
Since atypical hyperplasia increases the risk of 
developing invasive carcinoma 3-5 times, it requires 
establishing treatment standards. Although many authors 
recommend surgical treatment in those patients, we still 
lack algorithms regarding the size of excision.
The problem with diagnosing ADH begins with the 
differences in understanding what atypia means. In 1916 
Bloodgood introduced the term “borderline” for lesions 
about which “both the surgeon and pathologist are in 
doubt” [4]. Pathologists agree with a concept that atypical 
proliferative lesions exhibit some, but not all, features of 
carcinoma in situ. One definition characterizes ADH as 
having the cytological features of the non-necrotic forms 
of intraductal carcinoma with the changes may involve 
two or more ducts or ductules but measuring less than 
2 mm in aggregated diameter [5] Other authors do not 
include a measured dimension in their definition [6]. 
Some pathologists suggest that ADH and DCIS should 
form one diagnostic category termed “mammary intra-
epithelial neoplasia (MEN)” [7].
Borderline epithelial lesions, such as ADH, are very 
problematic and require very close cooperation between 
the pathologist, the radiologist and the surgeon.
The aim of this study was to perform a retrospective 
analysis of all observed cases of atypical ductal hyper-
pasia and to discuss the treatment of atypical ductal 
hyperplasia basing upon our own experiences and current 
publications regarding this subject.
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I n t r o d u c t i o n. Atypia is considered to be a risk factor for subsequent breast cancer, increasing the risk of developing 
malignancy 3-5 times. The diagnosis and treatment of atypical hyperplasia of the mammary gland is still controversial.
A i m. The aim of the study was to perform a retrospective analysis of all cases of atypical ductal hyperpasia and to discuss the 
treatment of atypical ductal hyperplasia basing upon our own experiences and current publications regarding this subject.
M e t h o d. 789 mammotomic biopsies of small breast lesions had been peroformed: 512 ultrasound-guided and 277 
stereotactic.
R e s u l t s. In case of 24 patients ADH was found in the histological specimen. There were 10 cases (1.9%) of atypical 
ductal hyperplasia in the ultrasound-guided biopsy group and 14 cases (5.0%) in the stereotactic biopsy group. Pathological 
examination of open biopsy specimens revealed 7 cases of fibro-cystic lesions, 3 cases of mild hyperplasia, 2 cases of atypical 
ductal hyperplasia and 2 cases of invasive carcinoma (ductal carcinoma and papillary carcinoma respectively). 10 (41.6%) 
patients with ADH had not been operated as they refused informed consent to an open surgical biopsy although they had 
been informed about the increased risk of breast malignancy.
C o n c l u s i o n. Upon our own experiences and current literature we recommend performing an open surgical biopsy in 
patients with atypical hyperplasia found in the mammotomic biopsy specimen.
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Material and methods
Between January 2001 and May 2004, 789 mammotomic 
biopsies of small breast lesions had been performed at the 
Regional Unit of Early Diagnosis of Breast Diseases at the 
First Department of General and Gastrointestinal Surgery in 
Krakow (Poland). Core biopsies were performed with the use of 
a prone multidirectional 11-gauge vacuum-assisted device with 
a minimum of 6 passes.
512 biopsies were ultrasound-guided and 277 were 
stereotactic. The ultrasound-guided biopsies were performed 
in patients with small (about 10 mm and less in diameter), 
solid lesions, not visualized in mammography and in patients 
with dense breast tissue in whom mammography is often 
falsely negative. Stereotactic biopsies were performed in 
patients with suspicious microcalcifications found in screening 
mammography. In case of stereotactic biopsies radiographs 
of the specimen were taken in order to confirm the inclusion 
of representative tissue. Only patients found to have atypical 
ductal hyperplasia on pathological examination were included 
in the analysis.
All histological specimens were stained with hemotoxilin-
eosin and the slides were reviwed by a fellow pathologist 
from the Department of Pathomorphology of the Collegium 
Medicum in Krakow, Poland.
All breast biopsies were performed under local anesthesia. 
After the removal of the specimen titanium markers were 
placed in the excised area. The patients were discharged after 
an observation period of one hour. On the next day all patients 
underwent control ultrasonography in order to monitor any 
post-biopsy complications.
The patients requiring further surgical treatment were 
operated at the 1st Department of General and Gastrointestinal 
Surgery in Krakow, Poland. Women with benign breast lesions 
on mammotomic biopsy had regular follow-up visits at the 
Regional Unit of Early Diagnosis of Breast Diseases. The first 
control examination after the biopsy was held three months 
after the procedure. The following visits were held at one-year 
intervals.
Results
Between January 2001 and May 2004 at the Regional 
Unit of Early Diagnosis of Breast Diseases of the 
First Department of General and Gastrointestinal 
Surgery in Krakow, Poland we had performed a total 
of 789 consecutive vacuum-assisted core biopsies (512 
ultrasound-guided and 277 stereotactic) in 789 women.
Patients with atypical ductal hyperplasia found in 
the specimen were analysed. This group consisted of 
24 women. In the entire group of 789 biopsied patients 10 
(1.9%) ADH patients had undergone ultrasound-guided 
biopsy and 14 (5.0%) – stereotactic biopsy. The mean 
age of this patient group was 54 years (range: 30-72). 13 
(54.2%) biopsies were obtained from the right breast, 
and 11 (45.8%) from the left breast.
Only 4 (12.5%) women presented with symptoms 
prior to diagnosis. Three patients had a palpable lump 
of less than 10 mm in diameter while one woman com-
plained of pain in the breast. The remaining 20 patients 
(87.5%) were asymptomatic and the diagnosis had 
been made in the course of mammographic screening 
or ultrasound. The lumps which were palpable during 
physical examination were visualized as hypoechogenic 
well-circumscribed areas in the ultrasound examination 
and were not well visualised in the mammographic radio-
graphs. We observed complications in 3 cases, (12.5%); 
these patients had heamatomas and in the case of one of 
these patients surgical intervention was necessary.
The mean age at first menstruation was 14 years 
(range: 12-17). Ten women were premenopausal at the 
time of diagnosis. The mean age at last menstruation in 
the postmenopausal women was 50.6 years (range: 46-
57). The mean number of pregnancies was 2.2 (range 
0-5). Nine patients (37%) had hormonal therapy (from 1 
to 15 years). Three women (12.5%) had a family history 
of a first-degree relative with breast cancer.
Ten of the ADH patients (41.6%) had undergone 
no further surgical treatment. These women had refu-
sed informed consent to open surgical biopsy, although 
they had been informed about an increased risk of breast 
malignancy. These women were followed-up at six-month 
intervals. No ultrasound or mammography abnormalities 
had been found in those patients. As ADH also increases 
the risk of cancer in the contralateral breast it is neces-
sary to control both breasts regularly. Mean follow-up 
time was 42 months (range: 19-64 months). The rema-
ining 14 women (45.9%) underwent open biopsy after 
a localizing wire had been placed in the preset area under 
ultrasound or mammography control. Pathological exa-
mination of the specimens revealed 7 cases of fibro-cystic 
lesions, 3 cases of benign hyperplasia, 2 cases of atypical 
ductal hyperplasia and 2 cases of invasive carcinoma. 
(1 case of ductal carcinoma and one case of papillary 
carcinoma). Of these patients one underwent modified 
radical mastecomy, while the patient with papillary carci-
noma refused either radical treatment or regular follow-
up visits and was lost from the analysis.
Discussion
Atypical ductal hyperplasia is a quite rare but a very 
problematic diagnostic and therapeutic problem. Atypia 
is considered to be a risk factor of subsequent breast 
cancer, increasing the risk of developing a malignancy by 
some 3-5 times. According to some authors it is not only 
a risk factor but also a precursor to ductal carcinoma in 
situ and invasive cancer [3, 8]. The definition of atypia 
and the differentiation between hyperplasia, atypia 
and carcinoma in situ is very problematic. There is no 
strict definition of ADH and thus the judgment of the 
pathologist is often very subjective [6]. In our study we 
had cooperated with two pathologists well experienced 
in diseases of the breast. They both read the initial 
mamotomy and the surgical biopsy specimens. In our 
opinion this would assure a more accurate diagnosis of 
ADH.
In order to increase the oncological safety of diag-
nosing pathologies of the breast we recommend placing 
titanium clips in the area from which the mammotomic 
specimens are obtained, in case the patient requires any 
further diagnosis [9]. A marker allows to assure the sur-
geon and the radiologist that in the course of the subse-
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quent open biopsy the appropriate specimen is obtained 
[10].
Stereotactic and ultasound-guided vacuum assisted 
biopsies are used worldwide for the diagnosis of breast 
lesions. The qualification criteria for stereotactic biopsy 
include clustered calcifications or mass distortion found 
in screening mammography. The ultrasound-guided 
technique is recommended for diagnosing small (10 mm 
or less) solid lesions, which are not well visualized on 
mammography scans, in patients with dense breast tissue 
or in pregnant or breast-feeding women in whom mam-
mography is not indicated. Breast specialist are discus-
sing usefulness of vacuum-assisted biopsy in patients 
with widespread microcalcifications and with multifocal 
lesions.
In the course of the study we had to tackle a very 
difficult issue. We had not realized how problematic it 
would be to convince a patient determined to undergo 
a minimal surgical procedure, such as a mammotomic 
biopsy, to undergo subsequent surgery when necessa-
ry. In the analyzed group of women almost half of the 
patients with ADH refused an open surgical biopsy after 
mammotomy. We believe this may have been brought on 
by a low level of awareness as to the possible conseque-
nces of neglecting the treatment of proliferative lesions, 
such atypical hyperplasia.
We agree with the opinion that the incidence of 
ADH is lower in the case of solid lesions, as compared to 
microcalcifications [3, 11]. In our study we had observed 
ADH in 5% of patients who had undergone stereotactic 
biopsy and only in 2% of patients who had undergone 
ultrasound-guided biopsies. We are convinced that mam-
motomic biopsy may, in many cases, be insufficient for 
the diagnosis of breast lesions. Although in the course of 
the mammotomic biopsy we can obtain more tissue than 
in the course of a fine needle aspiration biopsy, yet this 
amount is still inadequate to estimate the extension of 
the proliferative process and the tumor-free margins.
New concepts have appeared in the literature sug-
gesting the methods of improving the diagnostics of 
ADH, however they are still experimental [12-14]. In the 
future, the use of monoclonal antibodies against puri-
nergic receptors expressed on the surface of atypical and 
cancerous cells may help establishing correct diagnosis 
and choosing optimal surgical treatment [15, 16].
Although a mammotomic biopsy is more cost effec-
tive than a surgical biopsy after needle localization yet in 
some cases open biopsy is a necessity. In cases like those 
analyzed in our study an open biopsy is obligatory for 
a number of reasons, especially because atypical hyperp-
lasia is a confirmed important risk factor of breast can-
cer and because in view of any suspicion the presence of 
a proliferative process treatment must be aggressive and 
radical. While reviewing literature we have come across 
a very important question to which we have also failed 
to provide an answer, what should be done in the case of 
patients with atypical hyperplasia in the initial mammo-
tomic biopsy confirmed by the presence of atypia in the 
open surgical biopsy specimen. It is very difficult to state 
how aggressively such patients should be treated.
The diagnosis and treatment of atypical hyperplasia 
of the mammary gland is still controversial. Basing upon 
our own experiences and current literature data we would 
recommend performing open surgical biopsy in patients 
with atypical hyperplasia in the mammotomic biopsy spe-
cimen. Such patients should be clearly informed as to the 
high risk of developing breast malignancy and ought to 
be regularly monitored in a breast disease center.
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